Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-3172023-04-01falseNo description of principal activity7falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 08390481 2023-04-01 2024-03-31 08390481 2022-04-01 2023-03-31 08390481 2024-03-31 08390481 2023-03-31 08390481 c:Director1 2023-04-01 2024-03-31 08390481 c:Director4 2023-04-01 2024-03-31 08390481 d:PlantMachinery 2023-04-01 2024-03-31 08390481 d:PlantMachinery 2024-03-31 08390481 d:PlantMachinery 2023-03-31 08390481 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 08390481 d:FurnitureFittings 2023-04-01 2024-03-31 08390481 d:FurnitureFittings 2024-03-31 08390481 d:FurnitureFittings 2023-03-31 08390481 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 08390481 d:ComputerEquipment 2023-04-01 2024-03-31 08390481 d:ComputerEquipment 2024-03-31 08390481 d:ComputerEquipment 2023-03-31 08390481 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 08390481 d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 08390481 d:CurrentFinancialInstruments 2024-03-31 08390481 d:CurrentFinancialInstruments 2023-03-31 08390481 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 08390481 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 08390481 d:ShareCapital 2024-03-31 08390481 d:ShareCapital 2023-03-31 08390481 d:RetainedEarningsAccumulatedLosses 2024-03-31 08390481 d:RetainedEarningsAccumulatedLosses 2023-03-31 08390481 c:FRS102 2023-04-01 2024-03-31 08390481 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 08390481 c:FullAccounts 2023-04-01 2024-03-31 08390481 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 08390481 2 2023-04-01 2024-03-31 08390481 6 2023-04-01 2024-03-31 08390481 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure
Company registration number: 08390481







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2024


PHARMSURE INTERNATIONAL LIMITED






































img36e6.png                        

 


PHARMSURE INTERNATIONAL LIMITED
REGISTERED NUMBER:08390481



STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
  
1,372
2,559

Investments
  
87
87

  
1,459
2,646

Current assets
  

Stocks
  
2,399
162,661

Debtors: amounts falling due within one year
  
562,182
157,243

Cash at bank and in hand
  
184,543
336,378

  
749,124
656,282

Creditors: amounts falling due within one year
  
(336,137)
(293,911)

Net current assets
  
 
 
412,987
 
 
362,371

Total assets less current liabilities
  
414,446
365,017

  

Net assets
  
414,446
365,017


Capital and reserves
  

Called up share capital 
  
1,800
1,800

Profit and loss account
  
412,646
363,217

  
414,446
365,017


Page 1

 


PHARMSURE INTERNATIONAL LIMITED
REGISTERED NUMBER:08390481


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2024

The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
A R Bufton
................................................
G R Nix
Director
Director


Date: 15 November 2024
Date:18 November 2024

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 


PHARMSURE INTERNATIONAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Pharmsure International Limited is a private company, limited by shares, registered in England and Wales. The
address of the registered office and principle place of business is given in the company information page of these financial statements. 
The significant accounting policies applied in the preparation of these financial statements are set out below.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Income and Retained Earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 


PHARMSURE INTERNATIONAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.3

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. 

Sale of goods

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:
the company has transferred the significant risks and rewards of ownership to the buyer;
the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of turnover can be measured reliably;
it is probable that the company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds.

 
2.6

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 


PHARMSURE INTERNATIONAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
25%
straight line
Fixtures and fittings
-
25%
straight line
Computer equipment
-
33%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Financial instruments

The company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 5

 


PHARMSURE INTERNATIONAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 7 (2023 - 7).







4.


Tangible fixed assets





Plant and machinery
Fixtures and fittings
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 April 2023
18,409
14,127
8,101
40,637



At 31 March 2024

18,409
14,127
8,101
40,637



Depreciation


At 1 April 2023
18,409
14,127
5,542
38,078


Charge for the year on owned assets
-
-
1,187
1,187



At 31 March 2024

18,409
14,127
6,729
39,265



Net book value



At 31 March 2024
-
-
1,372
1,372



At 31 March 2023
-
-
2,559
2,559


5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2023
87



At 31 March 2024
87




Page 6

 


PHARMSURE INTERNATIONAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

6.


Debtors

2024
2023
£
£


Trade debtors
93,677
46,920

Amounts owed by group undertakings
446,663
99,937

Prepayments and accrued income
21,842
10,386

562,182
157,243



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
55,209
100,317

Corporation tax
14,492
-

Other taxation and social security
43,279
27,404

Other creditors
69,864
69,236

Accruals and deferred income
153,293
96,954

336,137
293,911



8.


Related party transactions

At the reporting date, the company was owed £446,663 (2023:£99,937) from related parties. The balance can be found within debtors. No interest is being charged on this loan..
At the reporting date the company owed £69,236 (2023: £69,236) to the directors. The balance can be found within creditors due within one year. No interest is being charged on this loan.

 
Page 7